Preclinical antitumor activity of XK469 (NSC 656889) Patricia M LoRussoRalph ParchmentThomas H. Corbett OriginalPaper Pages: 287 - 296
Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo Ilaria PastroneMaurizio VialeMauro Esposito OriginalPaper Pages: 297 - 302
Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations David R. ShalinskyJohn BrekkenKrzysztof Appelt OriginalPaper Pages: 303 - 313
Pala Versus Streptozotocin, Doxorubicin, and Meccnu in the Treatment of Patients With Advanced Pancreatic Carcinoma Robert S. WitteLouise M. RyanPaul F. Engstrom OriginalPaper Pages: 315 - 318
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion I. RassmannR. ThödtmannA.-R. Hanauske OriginalPaper Pages: 319 - 324
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors Jordan D. BerlinDona B. AlbertiGeorge Wilding OriginalPaper Pages: 325 - 330
Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study Sarah A. TaylorDorothy J. GirouxS. Clifford Schold OriginalPaper Pages: 331 - 332
Oral etoposide for patients with advanced adenocarcinoma of the pancreas Eva ThomasPamela DumasJaffer A. Ajani OriginalPaper Pages: 333 - 335
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma William J. BergJohn McCaffreyRobert J. Motzer OriginalPaper Pages: 337 - 340
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma Richard PazdurDiana C. MedgyesyJames L. Abbruzzese OriginalPaper Pages: 341 - 346
Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124) Frederick J. MeyersDanika LewE. David Crawford OriginalPaper Pages: 347 - 351
A phase II trial of irinotecan in hormone-refractory prostate cancer David M. ReeseSimon TchekmedyianPeter J. Rosen OriginalPaper Pages: 353 - 359